Skin-sparing mastectomy and immediate latissimus dorsi flap reconstruction: a retrospective analysis of the surgical and patient-reported outcomes

Table 1 The clinico-pathologic characteristics of the study population

	Group 1 (n = 39)	Group 2 (n = 26)	P-value
	mean±SD (range)/n (%)	mean±SD (range)/n (%)
Age, years	49.64 ± 10.6 (21to 74)	46.6 ± 7.7 (33 to 64)	0.209
Follow-up, months	36.5 ± 26.3 (1.6 to 89.9)	30.4 ± 21.9 (1.6 to 84.1)	0.333
Pathology			0.446
Infiltrating ductal carcinoma	29 (74.4)	19 (73.1)
Ductal carcinoma in situ	8 (20.5)	7 (26.9)
Infiltrating lobular carcinoma	2 (5.1)	0
Tumor size, cm	2.1 ± 0.9 (0.2 to 4.8)	1.8 ± 0.9 (0.2 to 3.5)	0.304
Stage			0.274
0	8 (20.5)	7 (26.9)
I	16 (41.0)	13 (50.0)
IIA	10 (25.6)	3 (11.5)
IIB	4 (10.3)	3 (11.5)
IIIA	1 (2.6)	0
T			0.493
Tis	8 (20.5)	7 (26.9)
T1	17 (43.6)	13 (50.0)
T2	14 (35.9)	6 (23.1)
N			0.489
N0	32 (82.0)	23 (88.5)
N1	6 (15.4)	3 (11.5)
N2	1 (2.6)	0
Adjuvant chemotherapy			0.441
No	18 (46.2)	18 (69.2)
CMF^a	12 (30.8)	4 (15.4)
AC-T^b	3 (7.7)	1 (3.8)
TAC^c	3 (7.7)	2 (7.7)
FAC^d	3 (7.7)	1 (3.8)
Anti-hormone therapy			0.548
No	8 (20.5)	7 (26.9)
Yes	31 (79.5)	19 (73.1)
Radiotherapy			0.411
No	38 (97.4)	26 (100)
Yes	1 (2.6)	0
Local recurrence
No	39 (100)	26 (100)
Yes	0	0
Regional Metastasis			0.411
No	38 (97.4)	26 (100)
Yes	1 (2.6)	0

^aCMF:cyclophosphamide, methotraxate, flurouracil; ^bA, doxorubicin; C, cyclophosphamide; T, docetaxel; ^cT, docetaxel, A, doxorubicin, C, cyclophosphamide; ^dFAC: flurouracil, epirubicin, cyclophosphamide.

ISSN: 1477-7819